Pulse Biosciences Company Insiders
PLSE Stock | USD 19.63 1.84 10.34% |
Pulse Biosciences' insiders are aggressively buying. The analysis of insiders' sentiment of trading Pulse Biosciences stock suggests that all insiders are extremely bullish at this time. Pulse Biosciences employs about 56 people. The company is managed by 14 executives with a total tenure of roughly 131 years, averaging almost 9.0 years of service per executive, having 4.0 employees per reported executive.
Pulse Biosciences' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-12-13 | Robert W Duggan | Acquired 55256 @ 17.18 | View | ||
2024-12-11 | Robert W Duggan | Acquired 56054 @ 17.35 | View | ||
2024-05-20 | Burke Thomas Barrett | Acquired 10000 @ 8.56 | View |
Monitoring Pulse Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Pulse |
Pulse Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pulse Biosciences' future performance. Based on our forecasts, it is anticipated that Pulse will maintain a workforce of about 60 employees by February 2025.Pulse Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3815) % which means that it has lost $0.3815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7028) %, meaning that it created substantial loss on money invested by shareholders. Pulse Biosciences' management efficiency ratios could be used to measure how well Pulse Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 4, 2025, Return On Tangible Assets is expected to decline to -0.94. In addition to that, Return On Capital Employed is expected to decline to -1. At present, Pulse Biosciences' Debt To Assets are projected to increase slightly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 0.11, whereas Net Tangible Assets are forecasted to decline to about 26.1 M.The current year's Common Stock Shares Outstanding is expected to grow to about 58 M, whereas Net Loss is projected to grow to (54.4 M).
Pulse Biosciences Workforce Comparison
Pulse Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 22,266. Pulse Biosciences adds roughly 56.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Pulse Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulse Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulse Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pulse Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 3.0 | 6 | 2 | 5,417,466 | 74,656 |
2024-09-01 | 10.3333 | 31 | 3 | 8,715,982 | 1,324 |
2023-12-01 | 5.7143 | 40 | 7 | 2,221,721 | 231,287 |
2023-09-01 | 1.6 | 8 | 5 | 635,467 | 135,467 |
2023-06-01 | 3.5714 | 25 | 7 | 17,207,061 | 269,377 |
2021-06-01 | 12.0 | 12 | 1 | 3,251,493 | 1,485 |
2021-03-01 | 3.6667 | 11 | 3 | 177,092 | 1,610 |
2020-12-01 | 2.0 | 4 | 2 | 411,096 | 9,070 |
2019-06-01 | 5.5 | 11 | 2 | 146,754 | 38,992 |
2019-03-01 | 1.5 | 6 | 4 | 52,303 | 86,159 |
2018-06-01 | 6.0 | 6 | 1 | 96,353 | 7,168 |
2017-06-01 | 5.75 | 46 | 8 | 1,574,778 | 100,000 |
2017-03-01 | 6.0 | 12 | 2 | 322,991 | 0.00 |
Pulse Biosciences Notable Stakeholders
A Pulse Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pulse Biosciences often face trade-offs trying to please all of them. Pulse Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pulse Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kevin Danahy | President CEO | Profile | |
Burke Barrett | CEO President | Profile | |
Robert Duggan | Executive CoChairman | Profile | |
Darrin Uecker | Principal CTO | Profile | |
Patty Perla | Vice Resources | Profile | |
Sandra Gardiner | CFO Admin | Profile | |
JD Esq | General Secretary | Profile | |
Gansevoort MD | Chief Officer | Profile | |
Niv MD | Chief Surgery | Profile | |
Richard Nuccitelli | Chief Officer | Profile | |
Mitchell Levinson | Chief Director | Profile | |
Holly JD | VP Strategy | Profile | |
David Danitz | Senior Engineering | Profile | |
Edison Manuel | Vice Operations | Profile |
About Pulse Biosciences Management Performance
The success or failure of an entity such as Pulse Biosciences often depends on how effective the management is. Pulse Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pulse management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pulse management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.89) | (0.94) | |
Return On Capital Employed | (0.96) | (1.00) | |
Return On Assets | (0.82) | (0.86) | |
Return On Equity | (0.86) | (0.81) |
Please note, the presentation of Pulse Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pulse Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pulse Biosciences' management manipulating its earnings.
Pulse Biosciences Workforce Analysis
Traditionally, organizations such as Pulse Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pulse Biosciences within its industry.Pulse Biosciences Manpower Efficiency
Return on Pulse Biosciences Manpower
Revenue Per Employee | -161 | |
Revenue Per Executive | -643 | |
Net Loss Per Employee | 753.8K | |
Net Loss Per Executive | 3M | |
Working Capital Per Employee | 689.6K | |
Working Capital Per Executive | 2.8M |
Complementary Tools for Pulse Stock analysis
When running Pulse Biosciences' price analysis, check to measure Pulse Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulse Biosciences is operating at the current time. Most of Pulse Biosciences' value examination focuses on studying past and present price action to predict the probability of Pulse Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulse Biosciences' price. Additionally, you may evaluate how the addition of Pulse Biosciences to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |